Preclinical evaluation reveals two novel gallium-68 labeled peptide radiotracers for prostate cancer, highlighting their diagnostic utility for positron emission tomography imaging.
Gastrin releasing peptide receptor (GRPR) is overexpressed in prostate cancer (PC-3) and can be used for diagnostic purposes. We herein present the design and preclinical evaluation of two novel NOTA/NODAGA-containing peptides suitable for labeling with the positron emission tomography (PET) radionuclide Ga-68. These analogs are based on the previously reported GRPR-antagonist DOTAGA-PEG2-[Sar
No takes yet. Share an insight, caveat, or question.
Kanellopoulos et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: